Ultragenyx is a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases.
View all
NeoGenomics
Fort Myers, United States · Post IPO Equity
Sema4
Stamford, United States · Post IPO Equity
Legend Biotech
Piscataway, United States · Post IPO Equity
Atara Biotherapeutics
South San Francisco, United States · Post IPO Equity
Aimmune Therapeutics
Brisbane, United States · Post IPO Equity
Biohaven Pharmaceuticals
New Haven, United States · Post IPO Equity
Sage Therapeutics
Cambridge, United States · Post IPO Equity
Sarepta Therapeutics
Cambridge, United States · Post IPO Equity
Insmed
Bridgewater, United States · Post IPO Equity
Veracyte
South San Francisco, United States · Post IPO Equity
Standard BioTools
South San Francisco, United States · Post IPO Equity
NanoString
Seattle, United States · Post IPO Equity